| Nov 15 |
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Fractyl Health Third Quarter 2024 Earnings: US$0.48 loss per share (vs US$9.61 loss in 3Q 2023)
|
| Nov 12 |
Fractyl Health reports Q3 resultsa
|
| Nov 12 |
Fractyl Health Reports Third Quarter 2024 Financial Results and Provides Business Updates
|
| Nov 12 |
Earnings Scheduled For November 12, 2024
|
| Nov 4 |
Fractyl Health to Present New Preclinical Data on Sustained Weight Maintenance and Blood Sugar from its Rejuva® RJVA-001 Single-Administration GLP-1 Pancreatic Gene Therapy Candidate at ObesityWeek® 2024
|
| Nov 4 |
Fractyl Health Presented New Analysis from Pooled Data of Revita® Clinical Studies Demonstrating Durable Weight Loss Maintenance for One Year at ObesityWeek® 2024
|
| Oct 29 |
Fractyl Health to Report Third Quarter 2024 Financial Results and Provide Business Updates on November 12, 2024
|
| Oct 28 |
Fractyl Health to Present Compelling Weight Maintenance Data from both Revita® and Rejuva® Platforms at ObesityWeek® 2024
|
| Sep 24 |
Fractyl Health to Present at Chardan’s 8th Annual Genetic Medicines Conference
|
